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Alzheimer’s disease (AD) is a neurodegenerative disorder hallmarked by the accumulation of extracel-
lular amyloid-b (Ab) peptide and intraneuronal hyperphosphorylated tau, as well as chronic neuro-
inflammation. Tauroursodeoxycholic acid (TUDCA) is an endogenous anti-apoptotic bile acid with potent
neuroprotective properties in several experimental models of AD. We have previously reported the
therapeutic efficacy of TUDCA treatment before amyloid plaque deposition in APP/PS1 double-transgenic
mice. In the present study, we evaluated the protective effects of TUDCA when administrated after the
onset of amyloid pathology. APP/PS1 transgenic mice with 7 months of age were injected intraperito-
neally with TUDCA (500 mg/kg) every 3 days for 3 months. TUDCA treatment significantly attenuated Ab
deposition in the brain, with a concomitant decrease in Ab1-40 and Ab1-42 levels. The amyloidogenic
processing of amyloid precursor protein was also reduced, indicating that TUDCA interferes with Ab
production. In addition, TUDCA abrogated GSK3b hyperactivity, which is highly implicated in tau
hyperphosphorylation and glial activation. This effect was likely dependent on the specific activation of
the upstream kinase, Akt. Finally, TUDCA treatment decreased glial activation and reduced proin-
flammatory cytokine messenger RNA expression, while partially rescuing synaptic loss. Overall, our re-
sults suggest that TUDCA is a promising therapeutic strategy not only for prevention but also for
treatment of AD after disease onset.
 2015 Elsevier Inc. All rights reserved.1. Introduction
Alzheimer’s disease (AD) is the most common form of dementia,
leading to memory impairment and progressive cognitive decline
(Reitz and Mayeux, 2014). AD is pathologically hallmarked by the
presence of extracellular senile plaques composed of amyloid-b
(Ab) peptide aggregates, intraneuronal neurofibrillary tangles
(NFTs) composed of hyperphosphorylated tau protein, and chronic
neuroinflammation (Selkoe, 2001). Senile plaques occur mainly as
deposits of amyloid fibrils surrounded by dystrophic neurites
(Selkoe, 2001). Ab peptides, containing 39-43 residues, derive
from the sequential proteolysis of the amyloid precursor protein
(APP), a single-pass transmembrane glycoprotein with a large
extracellular domain (Haass et al., 2012; Selkoe, 2001). The first step
of the amyloidogenic processing of APP is mainly catalyzed by beta-
site APP cleaving enzyme 1 (BACE1), the canonical b-secretase,r Medicines (iMed.ULisboa),
649-003, Portugal. Tel.: þ351
mprodrigues@ff.ul.pt (C.M.P.
ll rights reserved.leading to the shedding of the ectodomain (soluble APP-b fragment
or sAPP-b) and the production of a small membrane-spanning C-
terminal fragment b (CTF-b). CTF-b is further cleaved by g-secretase
in the transmembrane domain, generating Ab and releasing C-ter-
minal fragment g into the cytoplasm (Haass et al., 2012). Mutations
in the genes coding for APP and presenilin 1 (PS1), the catalytic core
of g-secretase, are respectively associated with increased amyloi-
dogenic processing of APP and preferential production of longer Ab
species with higher amyloidogenic propensity, such as Ab1-42
(Selkoe, 2001). Several of these mutations have beenwidely used in
the establishment of a plethora of mouse models of Ab pathology
(Elder et al., 2010). Nevertheless, other AD-associated phenotypes
are differentially observed among the available transgenic models,
with none of them fully recapitulating the cognitive decline
described in AD patients (Webster et al., 2014). In fact, over-
expression of APP and/or PS1 using artificial promoters poses
several drawbacks such as overproduction of APP and its cleavage
fragments besides Ab, which also impact on AD-associated phe-
notypes (Born et al., 2014; Saito et al., 2014). Furthermore, the vast
majority of mouse models manifest global neuronal death only
severalmonths aftermost AD-associated features are already firmly
P.A. Dionísio et al. / Neurobiology of Aging 36 (2015) 228e240 229established (Kokjohn and Roher, 2009). Still, APP/PS1 double-
transgenic mice are among the most successful models, promptly
developing Ab deposition and a robust neuroinflammatory
response toward Ab plaques, along with synaptic integrity loss, and
memory and cognitive impairments (Nunes et al., 2012; Radde
et al., 2006). Ab aggregation can elicit the development of inflam-
matory processes and increased gliosis, culminating in the abun-
dant presence of activated microglia and reactive astrocytes in the
vicinity of Ab plaques (Selkoe, 2001). During the progression of
AD, sustained glial activation increases the levels of secreted
proinflammatory molecules that, in turn, can induce their own
expression in a positive feedback loop. This mechanism further
exacerbates inflammation, ultimately contributing to neuro-
degeneration and dysregulation of signaling pathways that favor
the amyloidogenic processing of APP and tau hyperphosphorylation
(Meraz-Rios et al., 2013).
Glycogen synthase kinase 3 (GSK3) is a partially constitutively
active serine/threonine kinase ubiquitously expressed as 2 highly
homologous isoforms, GSK3a and GSK3b (Soutar et al., 2010).
Although both isoforms exert similar functions, they are differen-
tially expressed among cell types, with GSK3b being preferentially
expressed in the nervous tissue (Soutar et al., 2010). Importantly,
GSK3 hyperactivity has been extensively correlated with AD pa-
thology. GSK3b is known to phosphorylate tau and APP, which
probably contributes to NFT formation and increased amyloido-
genic processing of APP (Aplin et al., 1996; Durairajan et al., 2012;
Lee et al., 2003). GSK3b overactivation is also thought to impair
learning and memory (Zhu et al., 2007). Moreover, GSK3 can acti-
vate proapoptotic pathways in neurons exposed to insults usually
observed in AD (Mines et al., 2011). Finally, GSK3 is an important
regulator of the immune response, promoting the shift from anti-to
proinflammatory phenotypes in several cell types, including
microglia and astrocytes (Beurel and Jope, 2010; Koistinaho et al.,
2011; Yuskaitis and Jope, 2009). Inhibition of GSK3 in vivo has
already been proven to ameliorate all major AD-associated pa-
thologies (Durairajan et al., 2012; Sereno et al., 2009).
Tauroursodeoxycholic acid (TUDCA) is an endogenous hydro-
philic bile acid with strong anti-apoptotic properties in several
experimental models of neurodegeneration. In vitro studies
have determined that TUDCA inhibits Ab-induced apoptosis by
preventing caspase-2 activation and modulating p53-dependent
pathways (Ramalho et al., 2004, 2006; Sola et al., 2006; Viana
et al., 2010). Furthermore, TUDCA activates the prosurvival PI3K/
Akt signaling cascade, decreasing Ab-mediated apoptosis in pri-
mary rat cortical neurons (Sola et al., 2003). More importantly,
TUDCA enters the systemic circulation by oral administration and
is able to cross the blood-brain barrier (Keene et al., 2002). In this
respect, the neuroprotective effects of TUDCA have been demon-
strated in several animal models of neurodegenerative diseases,
including Huntington (Keene et al., 2001, 2002) and Parkinson’s
diseases (Castro-Caldas et al., 2012; Duan et al., 2002), and
ischemic and hemorrhagic stroke (Rodrigues et al., 2002, 2003).
We have previously reported the therapeutic efficacy of TUDCA in
APP/PS1 double-transgenic mice fed with a diet containing 0.4%
TUDCA for 6 months (Nunes et al., 2012). Notably, TUDCA treat-
ment significantly decreased Ab levels and deposition in mice
brain, markedly ameliorating memory deficits (Lo et al., 2013;
Nunes et al., 2012).
Given the promising results of TUDCA treatment before the
onset of amyloid pathology, we hypothesized that administration of
TUDCA at later stages is beneficial and ameliorates Ab pathology. In
this study, we used APP/PS1 mice to evaluate the protective effects
of TUDCA when administrated at 7 months of age. The results ob-
tained here further confirm the robust protective effects of TUDCA
as a potential therapeutic option for AD.2. Methods
2.1. Transgenic mice and treatment
APP/PS1 double-transgenic mice, maintained on a C57BL/6J genetic
background, coexpress KM670/671NL “Swedish” mutated human
APP695 and L166PmutatedhumanPS1under the regulatorycontrol of
a murine Thy-1 minigene promoter, which is a neuron-specific pro-
moter that restricts transgene expression to the postnatal period
(Radde et al., 2006). Mice were genotyped by polymerase chain reac-
tion (PCR) analysis of tail DNA. All animals were housed in standard
cages with ad libitum access to food and water in a temperature-
controlled environment with a 12-hour light/dark cycle. Male APP/
PS1 mice and wild-type littermates were randomly assigned to 4
groups: TUDCA-treated and untreated (control) wild-type mice and
TUDCA-treated and untreated (control) APP/PS1 mice. At 7 months of
age, animals were injected with either TUDCA (500 mg/kg of body
weight) or vehicle every 3 days for 3 months. The dosage of TUDCA
used was calculated based on previous studies developed in rodents,
includingAPP/PS1mice (Keene et al., 2002;Nunes et al., 2012). Animals
with 7 months of age were used to evaluate the protective effects
of TUDCA after the onset of amyloid pathology, because amyloid
deposition in APP/PS1 mice starts at 6 weeks in the neocortex and
2e3 months of age in the hippocampus (Radde et al., 2006).
2.2. Morris water maze
Spatial learning was evaluated in the Morris water maze as
previously described (Goddyn et al., 2006; Lo et al., 2013). Briefly,
mice were trained in a total of 10 days (specifically in 2 series of 5
training days, with 2 days of rest between each series) to find a
submerged platform. Four trials starting from 4 different starting
positions were performed each day with a trial interval of 30 mi-
nutes. When mice failed to find the hidden platform within 2 mi-
nutes, they were guided to the platform and were left there for 15
seconds, before being returned to their cages. Latency to find the
hidden platform was recorded with Ethovision (Noldus Bv, Wage-
ningen, the Netherlands). To evaluate retention memory, probe
trials were introduced on days 6 and 11. During these probe trials,
the platform was removed, and the swimming path was recorded
during 100 seconds. Time spent in each quadrant was measured.
2.3. Immunohistochemistry
Saline-perfused brains were excised, and one hemisphere was
snap frozen for protein extraction. The other hemisphere was fixed
in 4% paraformaldehyde for 48 hours and stored in 30% sucrose and
phosphate-buffered saline at 4 C. The treated hemispheres were
further dehydrated and embedded in paraffin. Sequential coronal
brain sections (4-mm thick) were obtained and mounted on
SuperFrost-Plus glass slides (Thermo Scientific, Rockford, IL, USA).
For immunostaining, brain sections were deparaffined and rehy-
drated, and antigen retrieval was performed by boiling the sections
for 20 minutes in 10 mM citrate buffer, pH 6.
The sections were then blocked for 1 hour in Tris-buffered saline
(TBS) containing 10% (vol/vol) normal donkey serum (Jackson
ImmunoResearch Laboratories Inc, West Grove, PA, USA) and 0.1%
(vol/vol) Triton X-100 (Sigma-Aldrich) and subsequently incubated
in appropriately diluted primary antibodies overnight at 4 C. After
washing with TBS/0.025% Tween20, the primary antibodies were
developed with diluted (1:200) Alexa Fluor 568 (anti-mouse) or
Alexa Fluor 594 (anti-rabbit) conjugated secondary antibodies
(Invitrogen) for 2 hours at room temperature. After rinsing, the
sections were counterstained with Hoechst 33,258 (Sigma-Aldrich)
and mounted on Fluoromount (Sigma-Aldrich). The following
Table 1
Primer sequences used to amplify indicated mouse cDNAs






Key: BACE1, beta-site APP cleaving enzyme 1; cDNA, complementary DNA;
HPRT, hypoxanthine-guanine phosphoribosyltransferase; IL-1b, interleukin-1b;
IL-6, interleukin-6; TNF-a, tumor necrosis factor-a.
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mouse monoclonal anti-Ab antibody (6E10; Covance; 1:1000); as-
trocytes were stained with a mouse monoclonal anti-glial fibrillary
acidic protein (GFAP) antibody (GA5; Millipore Corporation,
Temecula, CA, USA; 1:200); microglia were stained with a rabbit
polyclonal anti-Iba-I antibody (Wako Pure Chemicals, Richmond,
VA, USA; 1:100); p-APP was stained with a rabbit polyclonal anti-p-
APP (Thr668) antibody (Cell Signaling; 1:200); APP was stained
with a rabbit polyclonal anti-APP, C-terminal antibody (Sigma-
Aldrich; 1:200); p-tau was stained with a rabbit polyclonal anti-p-
tau (Ser396) antibody (101815; Santa Cruz Biotechnology; 1:50);
and presynaptic terminals were stained with a mouse monoclonal
anti-synaptophysin (SYN) antibody (SY38; Millipore; 1:100).
2.4. Histochemistry
After deparaffinization and rehydration, sections were stained with
Thioflavin T, a highly sensitive marker of Ab deposits. Staining was per-
formed with 0.05% Thioflavin T (Sigma-Aldrich) solution in phosphate-
buffered saline for 8 minutes at room temperature (Nunes et al., 2012).
2.5. Image analysis
All images were captured using an Axioskop fluorescence mi-
croscope (Carl Zeiss GmbH, Hamburg, Germany). At least 8 images
per hippocampal and cortical regions were acquired for each animal
and converted to gray scale with an 8-bit format. Semiquantitative
analysis of GFAP, Iba-I, SYN, and p-tau were performed with ImageJ
version 1.46r software (National Institute of Health, Bethesda, MD,
USA). The background of each set of images was subtracted, and a
threshold optical density was determined and held constant. Mean
gray values obtained for GFAP, Iba-I, SYN, and p-tau immunostaining
in the 4 mice groups were normalized to the mean gray values units
of control wild-type mice and are presented as percentage of wild-
type control mice. The number of Ab-plaques stained with Thio-
flavin T or 6E10 antibody were counted and presented as plaque
number per square millimeter for both hippocampus and frontal
cortex. Measurement of amyloid (Thioflavin) and Ab (6E10) burden
were also performed in thresholded images by applying an unbiased
computer-assisted image analyzer available in the ImageJ software,
whichwas used to quantify the areas occupied by positive staining in
the regions of interest. Amyloid and Ab burden was then calculated
by normalizing the reactive area to the total area of the regions of
interest and is presented as percentage of the total area.
2.6. Real-time PCR
Dissected hippocampus and frontal cortex were homogenized in
TRIzol (Invitrogen) using a motor-driven Bio-vortexer (No1083;
Biospec Products, Bartlesfield, OK, USA). After homogenization,
total RNAwas isolated according to themanufacturer’s protocol and
quantified using a Qubit 2.0 fluorometer (Invitrogen). Total RNAwasconverted into complementary DNA using Superscript II Reverse
Transcriptase (Invitrogen) according to the manufacturer’s in-
structions. Quantitative real-time PCR analyses were performed in
the 7300 Real-Time PCR System (Applied Biosystems, Foster City,
CA, USA), using SYBR Green PCR master mix (Fermentas Interna-
tional Inc, Glen Burnie, Maryland, USA). The expression levels of the
genes of interest relative to the housekeeping gene hypoxanthine-
guanine phosphoribosyltransferase were calculated using the DDCt
method. Control wild-type mice were used as the calibrator, and
the relative changes in gene expression were calculated according
to the formula 2DDCt. Primer sequences are presented in Table 1.
2.7. Western blot analysis
Dissected hippocampus and frontal cortex were homogenized in
TRIzol, and total protein extracts were obtained from TRIzol-
chloroform fractions (Simoes et al., 2013). Protein concentrations
were calculated using the Bio-Rad protein assay kit, according to the
manufacturer’s recommendations. Equal amounts of protein (60 mg)
were electrophoretically resolved on denaturing 8% or 12% poly-
acrilamide gels. To evaluate Ab and APP levels with the corre-
sponding cleavage products (sAPP-b and CTF-b), 60 mg of total
protein extracts were electrophoretically separated in 10%e20%
TriseTricine gels (Bio-Rad). The resolved proteins were transferred
onto nitrocellulose membranes, and blocking was performed with a
5% milk solution. Membranes were then incubated with the
following primary antibodies: rabbit polyclonal anti-p-APP (Thr668)
antibody (3823; Cell Signaling); rabbit polyclonal anti-APP, C-ter-
minal antibody (A8717; Sigma-Aldrich); mouse monoclonal anti-Ab
antibody (6E10; Covance), used to detect both total Ab peptide and
CFT-b; mouse monoclonal antibody anti-sAPP-b fragment with the
Swedish mutation (sAPP-b; 6A1; Immuno-Biological Laboratories,
Inc, Minneapolis, MN, USA); mouse monoclonal anti-GFAP antibody
(GA5; Millipore Corporation, Temecula, CA, USA); rabbit polyclonal
anti-p-Akt (Ser473) antibody (7985; Santa Cruz Biotechnology);
rabbit polyclonal anti-Akt (8312; Santa Cruz Biotechnology); rabbit
polyclonal anti-p-GSK3a/b (Ser21/9) (9331; Cell Signaling); mouse
monoclonal anti-GSK3 a/b antibody (7219; Santa Cruz Biotech-
nology); rabbit polyclonal anti-p-tau (Ser396) (101815; Santa Cruz
Biotechnology); and mouse monoclonal anti-tau (tau5; 58,860;
Santa Cruz Biotechnology). The membranes were then incubated
with goat secondary antibodies conjugated with horseradish
peroxidase anti-mouse or anti-rabbit (BioRad Laboratories, Hercules,
CA, USA) for 2 hours at room temperature. After rinsing with TBS/
0.2% Tween 20, the immunoreactive proteins were visualized with
ImmobilonWestern (Millipore) or SuperSignalWest Femto substrate
(Thermo Scientific). GAPDH (32,233; Santa Cruz Biotechnology) or b-
actin (AC-15; Sigma-Aldrich) were used as loading controls. Densi-
tometric analyses were performed with the Image Lab software
version 5.1 Beta (Bio-Rad). For APP cleavage fragments, Akt and
p-tau, each sample was analyzed twice to confirm the results.
2.8. Sandwich enzyme-linked immunosorbent assay
Sandwich ELISA kits (Millipore) were used to determine total
Ab1-40 and Ab1-42 concentrations from total protein extracts of
hippocampus and frontal cortex obtained from TRIzol-chloroform
fractions. TRIzol contains guanidine isothiocyanate, a strong dena-
turing agent, which allows for the recovery of total Ab present in
both soluble and insoluble fractions.
2.9. Statistical analysis
Data comparisons were conducted with 1-way analysis of vari-
ance (ANOVA) followed by post hoc Bonferroni test. Differences
Fig. 1. TUDCA treatment reduces amyloid plaque pathology in the brains of APP/PS1
mice. (A) Representative images of thioflavin staining in the hippocampus of control
wild-type mice and hippocampus and frontal cortex of TUDCA-treated and untreated
APP/PS1 mice. Scale bar, 100 mm. (B) Quantification of amyloid plaque number per
square millimeter in hippocampus and frontal cortex of TUDCA-treated and control
APP/PS1 mice. (C) Amyloid plaque burden presented as percentage of positive amyloid
staining area relative to the total area of interest in hippocampus and frontal cortex of
TUDCA-treated and untreated APP/PS1 mice. Values represent mean  SEM of 6e7
mice per group. yp < 0.01 and *p < 0.05 from control APP/PS1 mice. Abbreviations:
SEM, standard error of the mean; TUDCA, tauroursodeoxycholic acid. (For interpreta-
tion of the references to color in this Figure, the reader is referred to the web version of
this article.)
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test. Behavioral data obtained with the Morris water maze were
analyzed with 2-way ANOVA for repeated measures (RM), followed
by Tukey post hoc test. Analyses and graphical presentation were
performed with the GraphPad Prism software version 5 (GraphPad
Software, Inc, San Diego, CA, USA). Results are presented as mean 
standard error of the mean.
3. Results
3.1. Short-term treatment with TUDCA attenuates Ab deposition in
APP/PS1 mice
APP/PS1 mice show increased Ab production and parenchymal
Ab deposition beginning at 6 weeks of age, in the cortex, and at
2e3 months, in the hippocampus (Radde et al., 2006). In a previous
study, we demonstrated that TUDCA treatment started at initial
phases of Ab accumulation significantly prevented amyloid plaque
development (Nunes et al., 2012). In the present study,we evaluated
the effect of TUDCA on Ab deposition when administrated after the
onset of amyloid pathology in APP/PS1 mice, at 7 months of age.
Thioflavin T staining (Fig. 1A) and 6E10 immunolabeling (Fig. 2A)
revealed the presence of extensive amyloid deposits in the brains of
APP/PS1 mice, which were not observed in wild-type mice. Impor-
tantly, amyloid plaque number was significantly decreased in the
hippocampus of TUDCA-treated transgenic mice when compared
with control transgenic mice (p < 0.01), whereas no difference was
observed in the frontal cortex (Fig. 1B). Ab immunohistochemistry
further confirmed these results, showing approximately 50%
reduction in Ab plaque number in the hippocampus (p < 0.05)
(Fig. 2B). Moreover, amyloid burden, as evaluated by Thioflavin T
(Fig. 1C) and 6E10 staining (Fig. 2C) was decreased in the hippo-
campus and frontal cortex of TUDCA-treated APP/PS1 mice by
approximately 65% and 40%, respectively (p < 0.05). The cortex is
the first brain region affected by Ab deposition in this APP/PS1
mouse model (Radde et al., 2006). It has been demonstrated that
cortical formation of newamyloid plaques in thismodel occurs until
4e5 months of age and greatly decreases after this period, whereas
both newly formed and existing plaques appear to grow at a similar
rate (Hefendehl et al., 2011). Conversely, in the hippocampus, am-
yloid plaque formation only starts in the dentate gyrus at
2e3 months of age and in CA1 at 45 months of age (Radde et al.,
2006), which might explain the differences observed in overall
plaque burden and number between the frontal cortex and hippo-
campus with short-term TUDCA treatment (Figs. 1 and 2). Taken
together, these results demonstrate that TUDCA treatment attenu-
ates brain Ab deposition after the onset of amyloid pathology,
particularly in the hippocampus of APP/PS1 mice.
3.2. TUDCA reduces amyloidogenic processing of APP and Ab
generation in APP/PS1 mice
We have reported that preventive TUDCA treatment diminishes
amyloidogenic processing of APP in APP/PS1 mice, suggesting that
Ab reduction by TUDCA is the main mechanism underlying atten-
uated amyloid pathology (Nunes et al., 2012). To evaluate the effect
of short-term treatment with TUDCA on the amyloidogenic pro-
cessing of APP, we analyzed protein levels of APP b-secretase
cleavage products, sAPP-b, and CTF-b, by Western blot (Fig. 3).
Notably, sAPP-b fragment was significantly decreased both in the
hippocampus and frontal cortex (p < 0.05) of TUDCA-treated APP/
PS1 mice as compared with control APP/PS1 mice, while full-length
APP levels remained unchanged. CTF-b levels were also reduced in
Fig. 2. TUDCA treatment reduces Ab plaque pathology in the brains of APP/PS1
mice. (A) Representative images of Ab immunostaining (6E10) in the hippocampus
of control wild-type mice and hippocampus and frontal cortex of TUDCA-treated
and untreated APP/PS1 mice. Scale bar, 100 mm. (B) Quantification of Ab plaque
number per square millimeter in hippocampus and frontal cortex of TUDCA-treated
and control APP/PS1 mice. (C) Amyloid burden presented as percentage of positive
Ab immunoreactive area relative to the total area of interest in hippocampus and
frontal cortex of TUDCA-treated and untreated APP/PS1 mice. Values represent
mean  SEM of 6e7 mice per group. *p < 0.05 from control APP/PS1 mice. Ab-
breviations: Ab, amyloid-b; TUDCA, tauroursodeoxycholic acid. (For interpretation
of the references to color in this Figure, the reader is referred to the web version of
this article.)
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treated transgenic mice when compared with controls. In agree-
ment, total Abwas also significantly decreased in the hippocampus
(p < 0.05) and, to a lesser extent, in the frontal cortex (p < 0.05) of
TUDCA-treated APP/PS1 mice, indicating that short-term treatment
with TUDCA reduces the amyloidogenic processing of APP even at
later stages of amyloid pathology.
We have also used sandwich ELISA to evaluate Ab1-42 and Ab1-40
levels in both brain regions of the 4 mice groups studied. As ex-
pected, wild-type mice presented undetectable levels of either Ab1-
42 or Ab1-40 (data not shown). Furthermore, we determined that
both Ab1-42 and Ab1-40 levels were highly elevated in the brains of
APP/PS1 mice, with Ab1-42 exceeding Ab1-40 by several fold (Fig. 4).
Importantly, TUDCA treatment resulted in a significant reduction of
both Ab species in the hippocampus and frontal cortex of APP/PS1
mice, when compared with untreated transgenic mice (p < 0.05).
These findings indicate that TUDCA interferes with Ab generation
by reducing the amyloidogenic processing of APP after the onset of
the disease, thus representing a potential alternative for the exist-
ing therapeutic options.3.3. TUDCA supplementation alters Akt/GSK3b activities and
prevents tau hyperphosphorylation in APP/PS1 mouse brains
The Akt/GSK3 pathway is known to be deregulated in AD
(Durairajan et al., 2012; Lee et al., 2009; Malm et al., 2007; Ryder
et al., 2004). The serine/threonine kinase Akt is fully activated by
phosphorylation at serine 473, after other downstream effects
mediated by the phosphatidylinositol signaling pathway (Beaulieu
et al., 2009). In turn, GSK3b is a substrate of Akt that is inhibited by
phosphorylation of serine 9 (Beaulieu et al., 2009). In line with
these findings, we determined the levels of phosphorylated Akt
(p-Akt) and GSK3b (p-GSK3b) in brain lysates from TUDCA-treated
and untreated APP/PS1 mice. Consistent with others (Durairajan
et al., 2012), phosphorylation of Akt was significantly decreased
in the frontal cortex of control APP/PS1 mice relative to wild-type
mice (p < 0.05) (Fig. 5A). Noteworthy, the reduction in p-Akt
levels was reverted in TUDCA-treated transgenic mice (p < 0.05),
indicating increased activity of Akt with TUDCA treatment. Unex-
pectedly, our results showed no significant differences between Akt
phosphorylation levels in the hippocampus of control APP/PS1 and
control wild-type mice. In contrast, a trend to increase was
observed in p-Akt levels of TUDCA-treated wild-type mice relative
to control wild-type littermates, whereas a significant increase was
detected between TUDCA-treated and control APP/PS1 mice (p <
0.05), indicating that TUDCA can specifically activate Akt in the
hippocampus of wild-type mice.
Regarding p-GSK3b levels, they were significantly reduced in
both the hippocampus (p < 0.01) and frontal cortex (p < 0.005) of
control transgenic mice relative to wild-type controls (Fig. 5B).
Importantly, TUDCA treatment reverted the reduction observed in
p-GSK3b levels in APP/PS1 mice for both brain regions analyzed
(p < 0.005). Our findings suggest that TUDCA may abrogate AD-
associated GSK3b dysregulation, probably by specifically acti-
vating the upstream Akt signaling pathway.
Interestingly, it has recently been reported that specific GSK3b
inhibition resulted in decreased BACE1 messenger RNA (mRNA)
expression and protein levels in an ADmouse model (Ly et al., 2013).
Other authors have also described increased levels of BACE1 in AD
patient brains (Yang et al., 2003). Taking this into account, we eval-
uated if TUDCA modulation of the amyloidogenic processing of APP
was correlated with the bile acid effect on GSK3b activity and, sub-
sequently, BACE1 expression levels. However, this was not the case
Fig. 3. TUDCA treatment decreases the amyloidogenic processing of APP in the brains of APP/PS1 mice, as evaluated by the production of sAPP-b, CTF-b, and Ab. Representative
immunoblots of hippocampus and frontal cortex from control (n ¼ 5) and TUDCA-treated (n ¼ 5) wild-type mice, and control (n ¼ 6) and TUDCA-treated (n ¼ 7) APP/PS1 mice with
the respective densitometric analyses. b-Actin was used as loading control. Values are expressed as mean  SEM. yp < 0.01 and *p < 0.05 from control APP/PS1 mice. Abbreviations:
Ab, amyloid-b; APP, amyloid precursor protein; CTF-b, C-terminal fragment b; sAPP-b, soluble APP-b fragment; SEM, standard error of the mean; TUDCA, tauroursodeoxycholic acid.
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treatment, at both mRNA and protein levels (Supplementary Fig. 1).
Alternatively, other studies in vitro and in vivo suggest that GSK3b is
able to phosphorylate APP at threonine 668 (p-APP), which increases
Ab production (Aplin et al., 1996; Durairajan et al., 2012; Lee et al.,
2003) Therefore, we hypothesized that the effect of TUDCA on
GSK3b activity impacts on APP phosphorylation levels. Immunoblot
analyses revealed that p-APP levels were increased in the frontal
cortex of APP/PS1 mice comparing with wild-type mice (p < 0.05);
however, theywere unaffected by TUDCA treatment (Supplementary
Fig. 2A). We further analyzed APP phosphorylation by immunohis-
tochemistry and observed extensive accumulation of p-APP in
dystrophic neurites closely associated with amyloid plaques,
whereas total APP immunoreactivity was detected in both dystro-
phic neurites and neuronal perikaria (Supplementary Fig. 2B).
However, no changes were detected with TUDCA (Supplementary
Fig. 2B). These results are in agreement with previous studies in
AD patient brains and in mouse models (Lee et al., 2003) (Shin et al.,
2007). Curiously, p-APP immunoreactivity around amyloid plaques
was more extensively detected in the frontal cortex than in the
hippocampus of APP/PS1 mice (Supplementary Fig. 2B).
In respect to tau, it is known that the APP/PS1 mice used in this
study present hyperphosphorylated tau-positive neuritic structures
located in the proximity of amyloid plaques at 8 months of age, with
no significant NFT formation (Radde et al., 2006). Because GSK3b is
one of the major kinases implicated in tau hyperphosphorylation
(Leroy et al., 2010; Li and Paudel, 2006), we evaluated whether
TUDCA-dependent inhibition of GSK3bwas affecting p-tau levels. Tau
phosphorylation was determined by immunoblotting and immuno-
histochemistry using an antibody against tau phosphorylated at
Ser396 (corresponding to Ser936 of mouse origin), a residue already
identified as being specifically phosphorylated by GSK3b in the
absence of priming events (Leroy et al., 2010; Li and Paudel, 2006). As
depicted in Fig. 6A, p-tau levels were increased approximately 2-fold
in both hippocampus and frontal cortex (p < 0.05) of APP/PS1 micerelative to control wild-type mice. In contrast, TUDCA-treated
transgenic animals presented a strong reduction in p-tau levels in
both brain regions, showing a decrease of approximately 40% relative
to control APP/PS1 mice (p < 0.05). Immunohistochemical analyses
further revealed the presence of phosphorylated tau associated with
dystrophic neurites surrounding amyloid plaques (Fig. 6B). Quanti-
fication of phosphorylated tau immunoreactivity further confirmed
these results, supporting the view that the inhibitory effect of TUDCA
on GSK3b activity positively impacts on tau hyperphosphorylation.
3.4. TUDCA treatment ameliorates astrocytosis and microgliosis in
APP/PS1 mice
Amyloid deposition leads to extensive microgliosis and astro-
cytosis surrounding the affected areas in AD patients and mouse
models (Meraz-Rios et al., 2013; Selkoe, 2001). We have already
described that TUDCA supplementation mitigates the activation of
glial cells in APP/PS1 mice (Nunes et al., 2012). Interestingly, GSK3b
is emerging as a key enzyme involved in the regulation of pathways
and transcription factors involved in microglial and astrocytic
activation (Beurel and Jope, 2010; Koistinaho et al., 2011; Yuskaitis
and Jope, 2009). Because of the multiple lines of evidence showing
a TUDCA-dependent effect on both GSK3b phosphorylation levels
and glial activation, we assessed astrocytosis by GFAP immuno-
staining and immunoblot analyses, and microgliosis by Iba-I im-
munostaining. As expected, GFAP immunofluorescence showed a
prominent increase of reactive astrocytes in the hippocampus (p <
0.01) and frontal cortex (p < 0.005) of control APP/PS1 mice
compared with control wild-type mice (Fig. 7A and B). Noteworthy,
GFAP-reactive astrocytes were significantly reduced in both brain
regions of TUDCA-treated APP/PS1 mice compared with APP/PS1
controls (p < 0.05). Additionally, GFAP protein levels were also
evaluated by immunoblot, further confirming the dramatic increase
in GFAP levels in the hippocampus (p < 0.005) and frontal cortex
(p< 0.001) of control transgenicmice, when comparedwith control
Fig. 4. TUDCA reduces Ab1-42 and Ab1-40 levels in the brains of APP/PS1 mice, as
determined by ELISA. Quantification of Ab1-42 and Ab1-40 levels in the hippocampus
and frontal cortex of control and TUDCA-treated APP/PS1 mice. Data are expressed as
mean  SEM of 6e7 mice per group. *p < 0.05 from control APP/PS1 mice. Abbrevi-
ations: Ab, amyloid-b; ELISA, enzyme-linked immunosorbent assay; SEM, standard
error of the mean; TUDCA, tauroursodeoxycholic acid.
Fig. 5. TUDCA treatment increases Akt and GSK3b phosphorylation levels in the brains
of APP/PS1 mice. (A) Representative immunoblots of p-Akt (Ser473) and total Akt in the
hippocampus and frontal cortex of control and TUDCA-treated wild-type mice and
APP/PS1 mice, and respective densitometric analyses of the p-Akt to Akt ratio. (B)
Representative immunoblots of p-GSK3b (Ser9) and total GSK3b in the hippocampus
and frontal cortex of control (n ¼ 5) and TUDCA-treated (n ¼ 6) wild-type mice, and
control (n ¼ 6) and TUDCA-treated (n ¼ 7) APP/PS1 mice with the respective densi-
tometric analyses of the p-GSK3b to GSK3b ratio. Values are expressed as mean  SEM.
*p < 0.05, yp < 0.01, and zp< 0.005 from control wild-type mice and xp < 0.05 and {p <
0.01 from control APP/PS1 mice. Abbreviations: SEM, standard error of the mean;
TUDCA, tauroursodeoxycholic acid.
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mately 30% decrease in GFAP levels in the hippocampus and 45% in
the frontal cortex of TUDCA-treated APP/PS1 mice relative to APP/
PS1 controls (p < 0.05), further corroborating the results obtained
for GFAP immunostaining (Fig. 7C).
Microgliosis was significantly elevated in the hippocampus and
frontal cortex of control transgenic mice relative to wild-type mice
(p < 0.005) (Fig. 8A and B). Importantly, TUDCA treatment of APP/
PS1 animals decreased Iba-I immunofluorescence in both hippo-
campus and frontal cortex (p< 0.01). Because reactive microglia are
usually tightly clustered around amyloid deposits, we performed
double immunohistochemical staining with Iba-I and thioflavin to
evaluate the effect of TUDCA in amyloid-dependent microgliosis. In
accordance with previous reports, clusters of hypertrophic micro-
glia were detected in close proximity to Ab plaques in the brains of
control APP/PS1 mice, whereas less reactive microglia were visu-
alized surrounding amyloid plaques in the parenchyma of TUDCA-
treated transgenic mice (Fig. 8C).
To further characterize the effect of TUDCA on the proin-
flammatory response, we analyzed by quantitative real-time PCR
the expression levels of TNF-a, IL-1b, and IL-6, proinflammatory
cytokines extensively described as being augmented in AD (Meraz-
Rios et al., 2013). As anticipated, the mRNA levels of all 3 cytokineswere significantly elevated in both hippocampus and frontal cortex
of control APP/PS1 mice when compared with control wild-type
mice (Fig. 9), with TNF-a mRNA in the frontal cortex presenting
the highest increase (approximately 11-fold, p < 0.0001). TNF-a
mRNA levels were significantly decreased by TUDCA treatment both
in the hippocampus (p<0.05) and in the frontal cortex (p< 0.005) of
APP/PS1 mice relative to control APP/PS1 mice. IL-1b and IL-6 mRNA
levels showed no significant differences or a trend to decrease be-
tween these 2 groups, respectively. These results further indicate
that TUDCA reduces neuroinflammation in APP/PS1 mice.
3.5. TUDCA treatment reduces synaptic loss in APP/PS1 mice
Ab species and extensive gliosis have been widely implicated in
the neurodegenerative processes observed during AD progression.
However, transgenic mouse models of AD only manifest global
neuronal loss at very advanced ages, with our APP/PS1 model
presenting neuronal loss solely in the dentate gyrus of the hippo-
campus at 17 months of age (Radde et al., 2006; Wirths and Bayer,
2010; Rupp et al., 2011). On the other hand, soluble Ab oligomers
Fig. 7. TUDCA treatment attenuates astrogliosis in the brains of APP/PS1 mice. (A)
Representative images of GFAP immunostaining in the hippocampus of control
wild-type mice and hippocampus and frontal cortex of control and TUDCA-treated
APP/PS1 mice. Scale bar, 25 mm. (B) Quantification of GFAP mean gray values in the
hippocampus and frontal cortex of control and TUDCA-treated wild-type mice and
APP/PS1 mice, presented as percentage of control wild-type mice (n ¼ 6e7 mice
per group). (C) Representative immunoblots of GFAP in hippocampus and frontal
cortex lysates from control (n ¼ 5) and TUDCA-treated (n ¼ 6) wild-type mice, and
control (n ¼ 6) and TUDCA-treated (n ¼ 7) APP/PS1 mice with the respective
densitometric analyses. GAPDH was used as loading control. Values are expressed
as mean  SEM. yp < 0.01, zp < 0.005, and xp < 0.001 from control wild-type mice
and *p < 0.05 from control APP/PS1 mice. Abbreviations: GFAP, glial fibrillary acidic
protein; SEM, standard error of the mean; TUDCA, tauroursodeoxycholic acid. (For
interpretation of the references to color in this Figure, the reader is referred to the
web version of this article.)
Fig. 6. TUDCA treatment reduces tau phosphorylation in the brains of APP/PS1 mice.
(A) Representative immunoblots of p-tau (Ser396) and total tau in the hippocampus
and frontal cortex of control (n ¼ 6) and TUDCA-treated (n ¼ 6) wild-type mice, and
control (n ¼ 6) and TUDCA-treated (n ¼ 7) APP/PS1 mice with the respective densi-
tometric analyses of the p-tau to tau ratio. (B) Double staining of p-tau (red) and
amyloid plaques (thioflavin T, green) in the hippocampus and frontal cortex of control
and TUDCA-treated APP/PS1 mice. Scale bar, 25 mm. (C) Quantification of p-tau mean
gray values in the hippocampus and frontal cortex of control and TUDCA-treated APP/
PS1 mice, presented as percentage of control APP/PS1 mice (n ¼ 6e7 mice per group).
Values are expressed as mean  SEM. *p < 0.05 from control wild-type mice and yp <
0.05 and xp < 0.01 from control APP/PS1 mice. Abbreviations: SEM, standard error of
the mean; TUDCA, tauroursodeoxycholic acid. (For interpretation of the references to
color in this Figure, the reader is referred to the web version of this article.)
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contributing to loss of synaptic integrity and subsequently to
memory impairment and cognitive deficits (Selkoe, 2002). Inter-
estingly, several animal models of AD present loss of presynaptic
terminals, as determined by SYN immunostaining and protein
Fig. 8. TUDCA treatment reduces microgliosis in the brains of APP/PS1 mice. (A)
Representative images of Iba-I immunostaining in the hippocampus of control wild-
type mice and hippocampus and frontal cortex of control and TUDCA-treated APP/
P.A. Dionísio et al. / Neurobiology of Aging 36 (2015) 228e240236levels (Ding et al., 2008; Nunes et al., 2012; Radde et al., 2006). This
event starts as early as at 5 months of age in the hippocampal
dentate gyrus (Ding et al., 2008), indicating that APP/PS1 mice
models mimic the progression of synaptic dysfunction that is
observed early in patients with very mild to mild AD (Masliah et al.,
2001; Selkoe, 2002). The hippocampal dentate gyrus is highly
enriched in synaptic connections between the mossy fibers of the
dentate gyrus and the dendrites of the pyramidal neurons;
furthermore, the synaptic connections of this brain region are
commonly affected in APP/PS1 mice in an age-related manner, even
in regions devoid of amyloid plaques, which is thought to relate to
the development of memory deficits usually observed in these
models (Ding et al., 2008; Rutten et al., 2005). Consequently, we
proceeded to evaluate synaptic integrity in the dentate gyrus by
SYN immunostaining. As anticipated, semiquantitative analysis of
SYN immunostaining revealed an accentuated decrease in SYN
immunoreactivity in the polymorphic layer of the dentate gyrus of
control APP/PS1mice relative to control wild-typemice (p< 0.005),
whereas TUDCA treatment partially reverted this phenotype in
APP/PS1 mice (p < 0.05) (Fig. 10). These data indicate that TUDCA
administration even after the onset of AD pathology can still
partially protect from loss of synaptic function.
APP/PS1 double-transgenic mice undergo memory deterioration
due to the age-associated progression of Ab pathology (Radde et al.,
2006). To evaluate whether TUDCA administration ameliorates mem-
orydeficits in agedAPP/PS1mice, all animalswere trained in theMorris
water maze. During training, we measured no significant differences
between groups. All groups learned to locate the hidden platform
position over consecutive training days (2-way RM ANOVA: F9, 351 ¼
82.96, p< 0.001) and showed similar learning curves (Fig.11A). During
the second probe trial, we removed the platform and measured the
time mice spent in each of the different quadrants. We found a sig-
nificant quadrant (2-way RM ANOVA: F3, 117 ¼24.59, p < 0.001) and
quadrant by group effect (F9,117¼ 2.144, p< 0.05). Post hoc test shows
that both wild-type groups spent a significant amount of time in the
target quadrant (p< 0.001), whereas such a target quadrant preference
is lacking in control APP/PS1 mice (Fig. 11B). Nevertheless, a trend to
improved memory was detected, which probably correlates with
TUDCA-dependent attenuation of Ab pathology.
4. Discussion
AD is the most prevalent neurodegenerative disorder in aging
populations worldwide. Available treatments are mostly symptom-
atic andunable to arrest or revert the progression of the disease (Reitz
and Mayeux, 2014). In this regard, we have recently described a
remarkable rescue of different memory types, as well as improved
synaptic efficiency in APP/PS1 transgenic mice long-term treated
with neuroprotective TUDCA (Lo et al., 2013; Nunes et al., 2012;
Ramalho et al., 2013). Now, we extended our studies and further
demonstrated the therapeutic efficacy of TUDCAwhen administrated
at 7 months of age, after the onset of amyloid pathology. The rele-
vance of using transgenic mouse models to study AD has raised
several concerns because most of the clinical trials using AD thera-
peutic agents tested in mice result in negative therapeutic outcomesPS1 mice. Scale bar, 25 mm. (B) Quantification of Iba-I mean gray values in the hip-
pocampus and frontal cortex of control and TUDCA-treated wild-type mice and APP/
PS1 mice, presented as percentage of control wild-type mice. Values are expressed as
mean  SEM of 6e7 mice per group. yp < 0.005 from control wild-type mice and *p <
0.01 from control APP/PS1 mice. (C) Double staining of Iba-I and amyloid plaques
(thioflavin T staining) in the hippocampus of control and TUDCA-treated APP/PS1 mice.
Scale bar, 25 mm. Abbreviations: SEM, standard error of the mean; TUDCA, taur-
oursodeoxycholic acid. (For interpretation of the references to color in this Figure, the
reader is referred to the web version of this article.)
Fig. 10. TUDCA treatment partially rescues loss of presynaptic terminals. (A) Repre-
sentative images of SYN immunostaining in the hippocampus of control and TUDCA-
treated wild-type mice and APP/PS1 mice. Scale bar, 25 mm. (B) Quantification of
SYN mean gray values in the hippocampus of control and TUDCA-treated wild-type
mice and APP/PS1 mice, presented as percentage of control wild-type mice. Values are
mean  SEM of 6e7 mice per group. yp < 0.005 from control wild-type mice and *p <
0.05 from control APP/PS1 mice. Abbreviations: SEM, standard error of the mean; SYN,
synaptophysin; TUDCA, tauroursodeoxycholic acid. (For interpretation of the refer-
ences to color in this Figure, the reader is referred to the web version of this article.)
Fig. 9. TUDCA treatment decreases TNF-a mRNA expression in the hippocampus and
frontal cortex of APP/PS1 mice. Quantification of TNF-a, IL-1b, and IL-6 mRNA levels in
the hippocampus and frontal cortex of control and TUDCA-treated wild-type mice and
APP/PS1 mice. Data are expressed as mean  SEM of 6e7 mice per group as fold change
towards control wild-type mice. *p < 0.01, yp < 0.005, zp < 0.001 from control wild-type
mice and xp < 0.05 and {p < 0.005 from control APP/PS1 mice. Abbreviations: mRNA,
messenger RNA; SEM, standard error of the mean; TUDCA, tauroursodeoxycholic acid.
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PS1mice, remain instrumental for dissecting themolecular pathways
involved in AD and evaluating new therapeutic avenues.
Notably, our results suggest that although TUDCA treatment
does not completely revert amyloid pathology after its establish-
ment, it can still attenuate the progression of Ab deposition, as
confirmed by the diminished production of APP cleavage fragments
and decrease of total Ab levels in the hippocampus and frontal
cortex of APP/PS1 mice.
We have previously shown that TUDCA can activate the PI3K/Akt
signaling pathway, resulting in neuronal protection against Ab
toxicity (Sola et al., 2003). Interestingly, the Akt/GSK3 axis is
consistently deregulated in AD. The brains of AD patients demon-
strate decreased Akt activity that correlates to GSK3 hyperactivity, a
feature widely mimicked in vivo by transgenic mouse models used
to study AD, and in vitro by cell cultures harboring familial AD
mutations or exposed to Ab (Durairajan et al., 2012; Jia et al., 2013;
Lee et al., 2009; Ryder et al., 2004). GSK3b has also been extensively
associated with tau hyperphosphorylation (Leroy et al., 2010; Li and
Paudel, 2006).We showed that Akt activity was reduced in the frontal cortex of
APP/PS1 mice relative to control littermates although no significant
changes were observed in the hippocampus. However, GSK3b
was hyperactivated in both brain regions, which indicates that
hippocampal GSK3b dysregulation is probably independent of the
upstream Akt pathway. Although unexpected, the absence of dif-
ferences in Akt phosphorylation levels in the hippocampus, with a
concomitant decrease in GSK3b phosphorylation between wild-
type and APP/PS1 mice has also been demonstrated in APP/PS1
mice at 16 months of age (Malm et al., 2007). Controversially, other
studies have reported a reduction in both Akt and GSK3b phos-
phorylation levels in the hippocampus of 6- and 13-month-old APP/
PS1 mice (Hu et al., 2013; Jia et al., 2013). Interestingly, AD patients
appear to present reduced Akt phosphorylation in hippocampal
neurons only at end stage disease, when altered Akt activity is
already established in the cortex (Griffin et al., 2005; Lee et al.,
2009). Taken together, despite some controversy regarding Akt
activity levels in the hippocampus, it is plausible that hippocampal
Akt dysregulation correlates with affected neuronal integrity in this
brain region, which is manifest in transgenic mice only several
months after the development of other AD-related features.
Nevertheless, the role of TUDCA treatment in the modulation of
Akt/GSK3b signaling was highlighted by increased Akt activity in
Fig. 11. Cognitive performance in the Morris water maze in vehicle and TUDCA-treated
wild type mice and APP/PS1 mice. (A) During training, no significant group differences
were measured in time to find the hidden platform. All groups showed similar learning
curves. (B) During the second probe trial, we found a significant target quadrant
preference in both control and TUDCA-treated wild-type mice. Such preference was
not found in control APP/PS1 mice. TUDCA-treated APP/PS1 mice showed a trend to
target quadrant preference, albeit not significant (n ¼ 10 control wild-type mice; n ¼ 8
TUDCA-treated wild-type mice; n ¼ 11 control APP/PS1 mice; and n ¼ 14 TUDCA-
treated APP/PS1 mice). Data are expressed as means  SEM. *p < 0.001 between
target quadrant and all other quadrants, yp < 0.05 between target quadrant and A1
quadrant, and zp < 0.01 between target quadrant and opposite quadrant. Abbrevia-
tions: A1 and A2, adjacent quadrants; O, opposite quadrant, SEM, standard error of the
mean; T, target quadrant; TUDCA, tauroursodeoxycholic acid.
P.A. Dionísio et al. / Neurobiology of Aging 36 (2015) 228e240238the frontal cortex and hippocampus of APP/PS1 mice. Importantly,
this increase was correlated with inhibition of GSK3b activity and
tau hyperphosphorylation, suggesting that inactivation of GSK3b by
TUDCA positively modulates AD-associated tau pathology.
Although GSK3b has been also widely accepted as a major player
in several pathologic mechanisms associated with AD, the mecha-
nism by which this kinase regulates cerebral amyloidosis is still
somewhat controversial. Some authors have reported that GSK3b
inhibition downregulates BACE1 gene expression in APP23/PS45
double transgenic mice (Ly et al., 2013), whereas others did not
detected significant alterations in BACE1 protein levels (Ding et al.,
2008; Durairajan et al., 2012). Alternatively, GSK3b may be involved
in the phosphorylation of APP at the cytoplasmic residue Thr668,
targeting the protein for fast axonal transport to nerve terminals. Co-
localization of p-APP with b- and g-secretases within axonal orpresynaptic vesicles culminates in enhanced Ab generation
(Durairajan et al., 2012; Lee et al., 2003, 2005). This prompted us to
investigate whether TUDCA regulates APP processing and subse-
quent Ab production via GSK3b. Surprisingly, no significant changes
were detected in BACE1 levels between APP/PS1 mice and wild-type
littermates, treated or untreated with TUDCA. Similarly, TUDCA
administration did not impact onAPPphosphorylation. Still, there are
other kinases involved in AD pathology, such as cyclin-dependent
kinase 5 and c-Jun N-terminal kinase, that are postulated to phos-
phorylate APP, which might explain the unaltered p-APP levels
despite GSK3b inhibition (Durairajan et al., 2012).
Other aspect of GSK3 inhibition is the associated decrease of
glial activation and overall neuroinflammatory markers (Beurel and
Jope, 2010; Koistinaho et al., 2011; Yuskaitis and Jope, 2009). In this
context, GSK3b appears to upregulate the expression of several
proinflammatory mediators, such as TNF-a (Wang et al., 2010;
Yuskaitis and Jope, 2009), while decreasing anti-inflammatory
molecules (Koistinaho et al., 2011). Moreover, GSK3b inhibition
reduces microglial activation and migration (Yuskaitis and Jope,
2009), and increases inflammatory tolerance in astrocytes on
repeated inflammatory stimuli, suggesting a paramount role for
this kinase during chronic neuroinflammation (Beurel and Jope,
2010). As expected, a marked neuroinflammatory phenotype was
evident in the brains of APP/PS1, with a significant increase in
gliosis and upregulation of proinflammatory TNF-a, IL-1b, and IL-6.
Importantly, TUDCA administration after the onset of amyloid pa-
thology significantly ameliorated astrocytosis and microgliosis in
both hippocampus and frontal cortex of APP/PS1 mice and specif-
ically inhibited TNF-a mRNA expression. These results are in
agreement with others showing decreased levels of TNF-amRNA in
activated astrocytes treated with glycoursodeoxycholic acid but no
alterations in IL-1b expression (Fernandes et al., 2007). More
importantly, anti-TNF-a therapeutic strategies were reported to
reduce amyloid deposition, gliosis, and tau hyperphosphorylation,
rescuing cognitive and memory deficits in transgenic mice (Shi
et al., 2011; Tweedie et al., 2012). In addition, intrinsic anti-
inflammatory properties have also been attributed to TUDCA,
whichmay explain the striking results obtained for astrocytosis and
microgliosis in our model. TUDCA has been shown to decrease glial
activation and microglial migration in acute neuroinflammation
models both in vivo and in vitro (Yanguas-Casas et al., 2014). Finally,
TUDCA has also been reported to inactivate GSK3b and reduce
inflammation in liver tissue obtained after partial hepatectomy
(Ben Mosbah et al., 2010).
Other studies also showed the anti-inflammatory properties of
bile acids similar to TUDCA, such as ursodeoxycholic acid and gly-
coursodeoxycholic acid, in astrocytes and microglia exposed to
proinflammatory stimuli including Ab (Fernandes et al., 2007; Joo
et al., 2003). Because Ab accumulation is the main mechanism
involved in glial activation during AD (Meraz-Rios et al., 2013;
Radde et al., 2006), and GSK3b is also potentially involved, we
suggest that TUDCA-mediated effects on Ab load, GSK3b activity
and TNF-a expression are responsible for the reduced neuro-
inflammatory conditions in TUDCA-treated APP/PS1 mice. In this
regard, we are currently elucidating the molecular mechanisms by
which TUDCA protects from glial activation.
Activation of PI3K/Akt signaling is also crucial for the expression
of late-phase long-term potentiation (LTP), a form of synaptic
plasticity that is closely related with learning and memory, and
specifically affected in AD (Selkoe, 2002). This effect is particularly
important in the dentate gyrus of the hippocampus (Karpova et al.,
2006). Impairments in LTP may eventually culminate in synaptic
depression that in turn is correlated with structural changes in
synaptic morphology (Selkoe, 2002). Ab oligomers also inhibit LTP
and destabilize synaptic connection (Selkoe, 2002). Importantly,
P.A. Dionísio et al. / Neurobiology of Aging 36 (2015) 228e240 239treatment with TUDCA resulted in a reduction of presynaptic ter-
minals loss, as evidenced by an increase in the presynaptic marker
synaptophysin in the dentate gyrus of APP/PS1 mice. This effect
probably derives from the decrease in Ab load and activation of
PI3K/Akt by TUDCA. However, only a trend to improved spatial
memory was detected in TUDCA-treated APP/PS1 mice compared
with control APP/PS1 mice. Because this mouse model already
presents extensive cognitive deficits and memory impairment at
8 months of age (Radde et al., 2006), it is likely that TUDCA treat-
ment started at 7 months is not sufficient to revert emerging or
preestablished cognitive deficits. Still, mouse models do not
develop the same type of cognitive decline usually observed in AD
patients (Webster et al., 2014), which may also influence the
behavioral data.
In conclusion, our results demonstrate the therapeutic efficacy
of TUDCA in APP/PS1 mice with established amyloid pathology by
attenuating Ab production and deposition, tau pathology, glial
activation, and loss of synaptic function. Most of these effects are
likely related to the activation of the Akt/GSK3b signaling pathway.
However, modulation of Ab deposition may influence several
pathways that impact on tau hyperphosphorylation and neuro-
inflammation, which implicates that the reduction observed in Ab
load after TUDCA treatment may alter these AD-phenotypic traits
by GSK3b-independent pathways. Finally, because chronic neuro-
inflammation is also strongly associated with accelerated AD pro-
gression, the anti-inflammatory properties of TUDCA further
highlight its therapeutic potential. These evidences, allied to its
safety and brain bioavailability, point TUDCA as a promising ther-
apeutic strategy to attenuate AD progression.
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